cutaneous
cutaneous reactions
FDA
oncologic drugs
AE
CenterWatch
Inadequate and delayed characterization of cutaneous reactions for US Food and Drug Administration-approved oncologic drugs from 2011-2020 leading to medication discontinuation
Summary
- Half of clinical trials lack detailed descriptions of rashes; over half discontinue therapy due to rash.
- There's a 1- to 2-year delay from identifying a rash to fully characterizing it, although this has improved over the last decade.
- Oncologic therapies are often discontinued without consulting dermatologists, despite weak agreement on discontinuation decisions.
- In 86.4% of cases where dermatologists disagreed with discontinuation, they recommended against it.
- Early dermatology consultation reduces treatment interruptions and improves outcomes, quality of life, and adherence.
- The study highlights the need for early, comprehensive dermatologic involvement in drug development and trials.
- Limitations include the inability to examine conference presentations or FDA reports, which might offer earlier insights.
- Future research should assess the impact of early dermatology involvement in clinical trials for oncologic drugs.
Cutaneous reactions are common adverse events (AE) in oncologic drug clinical trials and a frequent reason for discontinuation. Although properly diagnosing cutaneous AEs and keeping patients on oncologic therapy is increasingly appreciated, many cutaneous AEs are not detailed in subsequent studies until long after their discovery, leading to unnecessary drug cessation and suboptimal management. We aimed to evaluate the extent to which cutaneous adverse events are described in oncologic trials and measure the delay from identification of a rash to its full characterization in the literature—parameters anecdotally appreciated as lacking but not examined in prior studies...
Click for Source
cutaneous, cutaneous reactions, FDA, oncologic drugs, AE, CenterWatch
